Table 1.

Analysis of LIBS expression in Osaka-12 αllbβ3

PMI-1AP5LIBS1LIBS6
(−)+FK633(−)+FK633(−)+FK633(−)+FK633
Control 1.53 ± 0.63 10.12 ± 4.14 0.95 ± 0.56 20.32 ± 7.78 16.59 ± 2.38 102.2 ± 14.66 2.24 ± 0.80 21.51 ± 1.53 
Osaka-12 4.3 ± 0.37 3.82 ± 0.77 5.59 ± 0.57 7.61 ± 0.53 12.15 ± 1.64 14.49 ± 4.96 7.36 ± 1.12 9.44 ± 0.43 
PMI-1AP5LIBS1LIBS6
(−)+FK633(−)+FK633(−)+FK633(−)+FK633
Control 1.53 ± 0.63 10.12 ± 4.14 0.95 ± 0.56 20.32 ± 7.78 16.59 ± 2.38 102.2 ± 14.66 2.24 ± 0.80 21.51 ± 1.53 
Osaka-12 4.3 ± 0.37 3.82 ± 0.77 5.59 ± 0.57 7.61 ± 0.53 12.15 ± 1.64 14.49 ± 4.96 7.36 ± 1.12 9.44 ± 0.43 

Washed platelets were incubated with or without 10 μM FK633 (αllbβ3-specific antagonist), and then each anti-LIBS antibody was added. After washing, bound antibodies were detected by FITC-conjugated goat F(ab′)2 antimouse IgG. Results are expressed as mean fluorescence intensity (MFI) ± SD of triplicate measurements. The MFI for MOPC21 used as a negative control was subtracted. Results are representative of 2 separate experiments.